About Enterprise Therapeutics
Enterprise Therapeutics is a company based in Brighton (United Kingdom) founded in 2014 by Martin Gosling was acquired by Roche in October 2020.. Enterprise Therapeutics has raised $86.19 million across 7 funding rounds from investors including Roche, Cystic Fibrosis Foundation and IP Group. The company has 9 employees as of December 31, 2021. Enterprise Therapeutics offers products and services including ETD001. Enterprise Therapeutics operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Ikaria and Pulmatrix, among others.
- Headquarter Brighton, United Kingdom
- Employees 9 as on 31 Dec, 2021
- Founders Martin Gosling
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Enterprise Therapeutics Ltd
- Date of Incorporation 02 May, 2014
- Jurisdiction BRIGHTON, ENGLAND
-
Annual Revenue
$1.69 M (USD)14as on Dec 31, 2021
-
Net Profit
$-5.76 M (USD)29as on Dec 31, 2021
-
EBITDA
$-7.37 M (USD)26as on Dec 31, 2021
-
Total Equity Funding
$86.19 M (USD)
in 7 rounds
-
Latest Funding Round
$33.02 M (USD), Series B
Jan 29, 2024
-
Investors
Roche
& 9 more
-
Employee Count
9
as on Dec 31, 2021
-
Acquired by
Roche
(Oct 07, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enterprise Therapeutics
Enterprise Therapeutics offers a comprehensive portfolio of products and services, including ETD001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhaled blocker targeting cystic fibrosis symptoms to improve breathing.
Unlock access to complete
Unlock access to complete
Leadership Team
7 people
Advisor Team
5 people
Head Team
3 people
Finance and Accounting
2 people
Unlock access to complete
Funding Insights of Enterprise Therapeutics
Enterprise Therapeutics has successfully raised a total of $86.19M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $33.02 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $33.0M
-
First Round
First Round
(11 Feb 2015)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Series B - Enterprise Therapeutics | Valuation | Panakes Partners | |
| Oct, 2019 | Amount | Grant - Enterprise Therapeutics | Valuation |
investors |
|
| Apr, 2018 | Amount | Series B - Enterprise Therapeutics | Valuation | Versant Ventures , Novartis Venture Fund |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enterprise Therapeutics
Enterprise Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Cystic Fibrosis Foundation and IP Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enterprise Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enterprise Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enterprise Therapeutics Comparisons
Competitors of Enterprise Therapeutics
Enterprise Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Ikaria and Pulmatrix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Precision medicines for lung-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of respiratory diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enterprise Therapeutics
Frequently Asked Questions about Enterprise Therapeutics
When was Enterprise Therapeutics founded?
Enterprise Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Enterprise Therapeutics located?
Enterprise Therapeutics is headquartered in Brighton, United Kingdom. It is registered at Brighton, East Sussex, United Kingdom.
Is Enterprise Therapeutics a funded company?
Enterprise Therapeutics is a funded company, having raised a total of $86.19M across 7 funding rounds to date. The company's 1st funding round was a Series B of $41.14M, raised on Feb 11, 2015.
How many employees does Enterprise Therapeutics have?
As of Dec 31, 2021, the latest employee count at Enterprise Therapeutics is 9.
What is the annual revenue of Enterprise Therapeutics?
Annual revenue of Enterprise Therapeutics is $1.69M as on Dec 31, 2021.
What does Enterprise Therapeutics do?
Enterprise Therapeutics was founded in 2014 and is based in Brighton, United Kingdom. Focus is placed on developing therapeutic solutions for respiratory diseases, including cystic fibrosis. Additional efforts are directed toward treatments for chronic obstructive pulmonary disease and severe asthma. Operations center on pharmaceutical research and development within the biotechnology sector, with activities conducted primarily in the UK.
Who are the top competitors of Enterprise Therapeutics?
Enterprise Therapeutics's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
What products or services does Enterprise Therapeutics offer?
Enterprise Therapeutics offers ETD001.
Who are Enterprise Therapeutics's investors?
Enterprise Therapeutics has 10 investors. Key investors include Roche, Cystic Fibrosis Foundation, IP Group, Imperial Innovations, and Panakes Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.